Jonathan Piccini, MD, MHS, Associate Professor of Medicine at Duke University and Duke Clinical Research Institute discusses goals for his forthcoming CHANGE AFib clinical trial. Dr. Piccini emphasizes this will be the first trial of its kind, focusing on patients at the time of first diagnosis with atrial fibrillation, which is the most common sustained abnormal heart rhythm. The CHANGE AFib study hopes to assess whether early implementation of rhythm control with dronedarone improves outcomes for patients with first-detected atrial fibrillation.